Dr Neil Berinstein joins IRX Therapeutics
This article was originally published in Scrip
Executive Summary
Dr Neil Berinstein has joined IRX Therapeutics (US) as chief scientific officer. He succeeds its founder Dr John Hadden, who remains a director of the company. Dr Berinstein has been working with IRX as a consultant. Before that, he served as assistant vice-president and global programme leader at Sanofi Pasteur, where he led the development of the company's cancer vaccines. IRX is a privately held company focused on the discovery and development of proprietary therapies for the treatment of cancer and viral diseases.